The Adverse Drug Reactions of Erythropoietin in Chronic Kidney Disease Patients

DOI

10.2991/978-94-6463-050-3_8How to use a DOI?

Keywords

Hemodialysis; Erythropoietin; Side Effects; Chronic Kidney Failure

Abstract

Anaemia is a severe problem for chronic kidney failure patients who want to maintain their quality of life. A decrease in erythropoietin production causes anaemia. Erythropoietin therapy is crucial in treating anaemia in chronic kidney failure patients. However, erythropoietin therapy can cause adverse drug reactions. This study aims to identify the case of adverse erythropoietin in chronic kidney failure patients in hospitals. This study implemented a cross-sectional observational design with prospective data collection on chronic kidney failure patients undergoing routine hemodialysis. The research subjects were patients who underwent routine hemodialysis and received erythropoietin therapy from October to December 2020 at the hemodialysis unit of Moewardi Hospital Surakarta and Universitas Negeri Surakarta Hospital. The data obtained from medical records and interviews with patients or families were then analyzed descriptively. The Naranjo algorithm was applied to determine whether the patients’ adverse reactions or complaints were related to the use of erythropoietin. The study subjects were 117 patients, consisting of 64 male patients (54.70%) and 53 female patients (45.30%). The most age range category of patients was 55–64 years by 38 patients (32.48%), and the length of hemodialysis record was 12–24 months (51.28%). Identification of adverse drug cases showed that 21 patients (7.92%) experienced side effects after using erythropoietin. The most prevalent side effects of using erythropoietin therapy were on the cardiovascular system in increased blood pressure and oedema in 12 patients (10.25%). The pharmacists should concern about the side effects of using erythropoietin in chronic kidney failure patients undergoing hemodialysis to minimize the risk in the anaemia treatment.

Copyright

© 2023 The Author(s)

Open Access

Open Access This chapter is licensed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license and indicate if changes were made.

Download article (PDF)

TY  - CONF
AU  - Isnaini Zuliastuti Mubarokah
AU  - Fita Rahmawati
PY  - 2022
DA  - 2022/12/14
TI  - The Adverse Drug Reactions of Erythropoietin in Chronic Kidney Disease Patients
BT  - Proceedings of the 4th International Conference Current Breakthrough in Pharmacy (ICB-Pharma 2022)
PB  - Atlantis Press
SP  - 77
EP  - 90
SN  - 2590-3195
UR  - https://doi.org/10.2991/978-94-6463-050-3_8
DO  - 10.2991/978-94-6463-050-3_8
ID  - ZuliastutiMubarokah2022
ER  -